At the recent European Academy of Allergy and Clinical Immunology Congress,Intellia Therapeutics, Inc. announced an update of the first part of the Phase I/II study of its CRISPR/Cas9 gene editing product NTLA-2002 for the prevention of inflammatory attacks in hereditary angioedema (HAE) patients. (Also see "Stock Watch: Not So Fast, Gene Editors" - Scrip, 5 July, 2021.)
The aim of NTLA-2002 is to inactivate the kallikrein B1 gene because C1 esterase inhibitor deficiency in HAE patients leaves...